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ABSTRACT
By inducing BK (bradykinin)-stimulated adrenomedullary catecholamine release, bolus injection of
the β-fragment of activated plasma coagulation Factor XII (β-FXIIa) transiently elevates BP (blood
pressure) and HR (heart rate) of anaesthetized, vagotomized, ganglion-blocked, captopril-treated
bioassay rats. We hypothesized that intravenous infusion of β-FXIIa into intact untreated rats
would elicit a qualitatively similar vasoconstrictor response. BN (Brown Norway) rats received
for 60 min either: (i) saline (control; n=10); (ii) β-FXIIa (85 ng/min per kg of body weight; n=9);
or (iii) β-FXIIa after 2ADX (bilateral adrenalectomy; n=9). LV (left ventricular) volume and
aortic BP were recorded before (30 min baseline), during (60 min) and after (30 min recovery)
the infusion. TPR (total peripheral resistance) was derived from MAP (mean arterial pressure),
SV (stroke volume) and HR. Saline had no haemodynamic effects. β-FXIIa infusion increased its
plasma concentration 3-fold in both groups. In adrenally intact rats, β-FXIIa infusion increased
MAP by 6% (5+ −2 mmHg) and TPR by 45% (0.50+ −0.12 mmHg/ml per min), despite falls in
SV (−38+ −8 μl) and HR [−18+ −5 b.p.m. (beats/min)] (all P<0.05). In 2ADX rats, β-FXIIa
had no HR effect, but decreased SV (−89+ −9 μl) and MAP (−4+ −1 mmHg), and increased
TPR by 66% (0.59+ −0.15 mmHg/ml per min) (all P<0.05). After infusion, adrenally intact rats
exhibited persistent vasoconstriction (MAP, 10+ −1 mmHg; TPR, 0.55+ −0.07 mmHg/ml per min;
both P<0.05), whereas in 2ADX rats, MAP remained 5+ −1 mmHg below baseline (P<0.05) and
TPR returned to baseline. End-study arterial adrenaline (epinephrine) concentrations in the three
groups were 1.9+ −0.6, 9.8+ −4.1 and 0.6+ −0.2 nmol/l respectively. Thus, in neurally intact lightly
anaesthetized untreated rats, β-FXIIa infusion induces both adrenal catecholamine-mediated and
adrenally independent increases in peripheral resistance.
INTRODUCTION
For decades after its initial discovery in 1955, FXIIa
(activated Factor XII) was considered exclusively an
element of the coagulation cascade [1]. However, it is
now appreciated that FXIIa also engages the ﬁbrinolytic
system, RAS (renin–angiotensin system), complement
system and KKS (kallikrein–kinin system) [2–4]. With
evidence for a positive relationship between plasma
FXIIa concentration and BP (blood pressure) now
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Abbreviations: 2ADX, bilateral adrenalectomy; BK, bradykinin; BN, Brown Norway; BP, blood pressure; b.p.m, beats/min; CO,
cardiac output; DBP, diastolic BP; FXIIa, activated Factor XII; β-FXIIa, β-fragment of FXIIa; HR, heart rate; KKS, kallikrein–
kinin system; LV, left ventricular; LVEDV, LV end-diastolic volume; LVESV, LV end-systolic volume; MAP, mean arterial pressure;
PACAP, pituitary adenylate cyclase-activating polypeptide; RVU, relative volume unit; SBP, systolic BP; SV, stroke volume; TPR,
total peripheral resistance.
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emerging from population studies [5–7], the question
arises whether such interactions between FXIIa and
peptides involved in cardiovascular regulation exert
important haemodynamic effects.
Previous work from our institution has identiﬁed a
novel physiological interaction between FXIIa and the
KKS and sympatho-adrenal system, leading to changes
in BP. Speciﬁcally, when injected into a rat bioassay,
an acute bolus (0.3–1 μg/kg of body weight) of the
β-FXIIa (β-fragment of FXIIa; which contains the se-
rine protease catalytic region [2–4]) stimulates the
release of adrenomedullary catecholamines [8,9], via a
non-cholinergic peptidergic mechanism of action [10],
resulting in marked, but transient, increases in both BP
and HR (heart rate) [11]. BP also increases if trypsin-
activated FXI (Factor XI)-deﬁcient plasma is injected,
but not if FXII-deﬁcient plasma is injected [11].
These acute sympatho-adrenal and cardiovascular
responses to β-FXIIa are augmented by pre-treatment
with captopril or enalapril [8,11], are attenuated by pre-
treatment with selective antagonists of BK (bradykinin)
B2 [12] and PACAP (pituitary adenylate cyclase-
activating polypeptide) PAC-1 [13] receptors, are absent
in both adrenal medullectomized rats and kininogen-
deﬁcient BN (Brown Norway) Katholiek rats [14],
and are blocked by combined α-a n dβ-adrenoceptor
blockade [8]. Taken together, these several observations
indicate that expression of this pressor response, which
is speciﬁc to β-FXIIa, requires both an intact KKS and
adrenal medullae.
Thus far, evidence for participation of plasma
coagulationFXIIainBPregulationhasbeenderivedfrom
such bolus injection experiments involving a bioassay
rat preparation characterized by low basal BP, HR
and plasma catecholamine concentrations. Whether this
coagulationfactor,whichisactivatedandwhichcirculates
in higher plasma concentrations chronically in several
conditions characterized by vascular inﬂammation or
injury [15–18], exerts functionally important haemody-
namic effects under conditions more representative of
normal circulatory physiology has yet to be determined.
The objectives of the present study therefore were
ﬁrst, to conﬁrm that the acute rise in BP observed in
response to a bolus injection of FXIIa in an antagonized
and vagotomized ACE (angiotensin-converting enzyme)
inhibitor-treated rat is also evident if FXIIa is given
by infusion to an innervated non-medicated rat; and
secondly, to characterize the haemodynamic mechanisms
responsible for any subsequent BP increase. On the
basis of this prior literature, our hypothesis was that a
60-min infusion of FXIIa would increase plasma
adrenaline (epinephrine) concentrations, and as a
consequence, TPR (total peripheral resistance) and BP.
This study was presented in part at the 22nd Congress
of the International Society on Thrombosis and Haemo-
stasis (ISTH), 11–16 July 2009, Boston, MA, U.S.A. [18a]
MATERIALS AND METHODS
Experimental preparation
Male BN rats (Rattus norvegicus) weighing 250–350 g
(Charles River Laboratories) were distributed into
three experimental groups: (i) saline infusion (control,
n=10); (ii) β-FXIIa infusion (n=9); and (iii) β-FXIIa
infusion following 2ADX (bilateral adrenalectomy,
n=9). Animals were cared for and studied in accordance
with the Canadian Council on Animal Care principles
andguidelines.Allexperimentalprotocolswereapproved
by the Advisory Committee on Animal Services of the
Division of Comparative Medicine, Faculty of Medicine,
University of Toronto. All animals were administered
isoﬂurane anesthetic (2–5%; Halocarbon Laboratories)
with a mixture of oxygen (BOC Gases) using a Fluotec
Mark 2 vaporizer (Cyprane) at a gas ﬂow rate of
3 litres/min until adequate depth of anaesthesia was
attained. 2ADX was performed prior to infusion only
in the 2ADX group. Brieﬂy, through a ventral midline
incision, both adrenal glands were located superior to
each kidney and isolated from surrounding adipose and
connective tissue, and excised. The abdomen was then
closed and sutured (3-0 Dexon; Ethicon) and the skin
incisionsclosedwith9 mmautoclips(BectonDickinson).
The right common carotid artery of all rats was cannu-
lated by a micro-tip pressure–volume catheter transducer
(SPR-838; Millar Instruments) advanced retrograde into
the left ventricle to record LV (left ventricular) pressure
and estimated volume throughout the cardiac cycle [19].
To record arterial BP, the right femoral artery was
cannulated with an ultra-miniature micro-tip pressure
catheter transducer (SPR-671; Millar Instruments)
advanced ∼12 cm towards the descending aorta, above
the renal arteries. To administer saline or coagulation β-
FXIIainfusions,theleftfemoralveinwascannulatedbya
polyethylenetubethatwasattachedtoa1 mlsyringecon-
nected to an infusion pump. Core body temperature was
monitoredandmaintainedat37◦Cusingahomeothermic
heating pad (HB-101-402; VWR). The dose of isoﬂurane
inhalation was reduced to maintain light anaesthesia
(0.75–1.25%; Halocarbon Laboratories). Only rats that
had sustained <1.5 ml blood loss during surgery and
exhibited stable BP and HR for at least 10 min after
surgery were studied. To collect blood for plasma β-
FXIIa and catecholamine determinations, on completion
of the experimental protocol, the pressure–volume
catheter was replaced by a second polyethylene tube.
Human coagulation β-FXIIa
As described previously [9,10], highly puriﬁed human
coagulation β-FXIIa (30 kDa, Lot β-FXIIa 1000P and
2070P; Enzyme Research Laboratories) was dissolved in
heparinizedsaline(0.9%NaClwith20 units/mlheparin)
to achieve a ﬁnal concentration of 10 ng/μl and divided
into 50 μl aliquots. All solutions of β-FXIIa were stored
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at −80◦C until use and kept on ice during experiments
to retard degradation.
Experimental protocol and
haemodynamic measurements
Data were acquired continuously over three consecutive
periods: baseline (0–30 min), femoral venous infusion (β-
FXIIaat85 ng/minperkgofbodyweightat10 μl/minor
physiological saline control at 10 μl/min; 30–90 min) and
recovery (90–120 min). Assuming that a rat has ∼15 ml
of blood containing ∼40 μg/ml of FXII zymogen [20]
(600 μg for a 300 g rat), the total dose of β-FXIIa infused
over60 min(5.1 μg/kgofbodyweight;1.53 μgfora300 g
rat),whichrepresents∼0.26%ofitstotalFXIIzymogen,
can be considered to lie well within its physiological
range. Alternatively, based on the Beer–Lambert law,
where concentration is proportional to absorbance, the
circulating FXIIa levels (0.86+ −0.05 A550 units) were
approximately <0.63% of the total FXII zymogen
content (1.37+ −0.09 A550 units; RATa diluted 1:100) [21].
The micro-tip pressure and pressure–volume catheter
transducers were each linked to a control unit (MPCU-
200; Millar Instruments) connected to a MacLab/8 data
acquisition system (AD Instruments) driven by Power-
Lab Chart v.4.2 software (AD Instruments). Arterial
SBP (systolic BP) and DBP (diastolic BP) were derived
from the BP waveform and are given in mmHg. MAP
(meanarterialpressure)wascalculatedusingtheequation
MAP=DBP+1/3 (SBP−DBP) and is given in mmHg.
HRwasderivedfromtheBPwaveformbycyclicvariable
analysis and is given in b.p.m. (beats/min). LVESP (LV
end-systolic pressure) and LVEDP (LV end-diastolic
pressure) were derived from the LV pressure waveform
and are given in mmHg. LV RVU (relative volume
units, arbitrary units) for systole (RVUmin) and diastole
(RVUmax) were derived from the volume waveform. In
a separate set of rat experiments, as described in the
Supplementary Online material (available at http://www.
clinsci.org/cs/122/cs1220581add.htm), a second-order
polynomial trend-line (y=−9×10−5x2 +0.0706x+
10.138) was derived to permit conversion of RVU (y)
intoabsoluteLVvolumemeasurements(x; μl).SV(stroke
volume)wasthencalculatedasLVEDV(LVend-diastolic
volume)–LVESV (LV end-systolic volume) and is given
in μl. CO (cardiac output; ml/min) was calculated as the
productof SV and HR.TPRwas derived fromMAP/CO
and is given in mmHg/ml per min.
Plasma coagulation β-FXIIa and
catecholamine measurements
At the end of the recovery period, arterial blood (500 μl
samples) were collected in 3.8% buffered citrate solution
(Vacutainer, blue-top; Becton Dickinson) for β-FXIIa
determinations, and in K2EDTA (365973, Microtainer,
lavender-top;BectonDickinson)forcatecholamineassay.
Samples were centrifuged immediately at 2000 g for
20 min at 4◦C. Plasma was separated and stored at
−80◦C in approximately 100 μl aliquots for analysis.
Plasma β-FXIIa was measured using a novel FXIIa
ELISA that employs mAb (monoclonal antibody) 201/9
which binds to conformational epitopes on the heavy
chain of β-FXIIa and exhibits no cross-reactivity with
FXII zymogen or FXIIa–inhibitor complexes [21]. Ad-
renaline and noradrenaline concentrations were determ-
ined using HPLC with electrochemical detection [22].
Statistical analysis
Numerical data are presented as means+ −S.E.M.
Statistical comparisons were analysed using Sigma Stat
program (version 2.03; SPSS). These investigations were
structured as if two separate studies, with ﬁndings
in the experimental group (β-FXIIa) compared ﬁrst
with its saline control, and subsequently to the group
into which β-FXIIa was infused subsequent to 2ADX.
Thus Student’s t test was used to compare baseline
values, plasma β-FXIIa and plasma catecholamine
concentrations between the β-FXIIa experimental group
and these two speciﬁc control reference groups (β-
FXIIa compared with control; β-FXIIa compared with
2ADX). As shown in Figure 1, the haemodynamic data
acquired over the entire experiment were averaged over
5 min intervals. To obtain means for subsequent analysis,
0–30 min data were averaged to obtain steady-state
baseline values, and for comparisons against baseline, 40–
90 mindatawereaveragedtoobtainsteady-stateinfusion
period values, and 100–120 min data were averaged
to obtain steady-state recovery period values. Steady-
state values within-treatment groups (baseline compared
with infusion compared with recovery) and between-
treatment groups (β-FXIIa compared with control; β-
FXIIa compared with 2ADX) were compared by two-
way ANOVA, applying the Student–Newman–Keuls
post hoc test for pairwise multiple comparisons. A value
for P<0.05 was required for statistical signiﬁcance.
RESULTS
Table 1 presents for the experimental group, and for the
two respective control groups, mean baseline data for
each of the haemodynamic variables studied. Apart from
TPR,therewerenodifferencesinbaselinehaemodynamic
values between the β-FXIIa and saline control group.
Removal of the adrenal gland resulted in signiﬁcantly
lower baseline BP, HR and TPR, yet signiﬁcantly higher
SV, as compared with the β-FXIIa experimental group.
Figure 1 illustrates BP, HR, LVEDV and LVESV, CO
andTPRat5 minintervalsbefore,duringandaftereachof
the three infusions. Figure 2 presents the haemodynamic
changes from pre-infusion baselines (i.e. the mean of 0–
30 min)duringboththesteady-stateinfusionperiods(i.e.
the mean of 40–90 min) and the steady-state recovery
periods (i.e., the mean of 100–120 min). Saline infusion
C   The Authors Journal compilation C   2012 Biochemical Society
© 2012 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.584 P. C. Papageorgiou and others
Figure 1 Time course of changes in arterial BP, MAP, HR, LV volume, CO and TPR before infusion, during infusion and over
a 30 min post-infusion recovery period in the control, β-FXIIa and 2ADX groups
Values are means+ −S.E.M. Baseline was from time 0–30 min. Infusions (10 μl/min for 60 min) were with saline (Control), or human coagulation β-FXIIa (85 ng/min
per kg of body weight) into either BN rats with intact adrenal glands (β-FXIIa) or into bilateral adrenalectomized BN rats (2ADX). In the arterial BP plot, the upper
values are the SBP and the lower values are the DBP. In the LV volume plot, the upper values are the LVEDV and the lower values are the LVESV.
(control group) did not change any haemodynamic
variable at any time (Figures 1 and 2).
Table 1 Haemodynamics at baseline
Values are means+ −S.E.M. (n=9 or 10; see text). ∗P <0.05 for the β-FXIIa
group compared with control group; †P <0.05 or ††P <0.01 for the
β-FXIIa group compared with the 2ADX group.
Haemodynamic variable Control β-FXIIa 2ADX
SBP (mmHg) 104+ −3 108+ −39 8 + −2†
DBP (mmHg) 55+ −66 3 + −34 8 + −3††
MAP (mmHg) 72+ −47 8 + −36 5 + −3††
LVEDV (μl) 383+ −26 353+ −36 372+ −26
LVESV (μl) 169+ −17 165+ −26 133+ −16
SV (μl) 215+ −14 188+ −10 239+ −17†
HR (b.p.m.) 405+ −11 394+ −10 326+ −15††
CO (ml/min) 88+ −77 4 + −67 7 + −5
TPR (mmHg/ml per min) 0.85+ −0.07∗ 1.12+ −0.08 0.89+ −0.07†
Haemodynamic changes during β-FXIIa
infusion
In the intact rats, β-FXIIa infusion caused a rapid
and sustained decrease in HR, a gradual reduction in
LVEDV and LVESV, with only the latter returning
to baseline, and a gradual and sustained reduction in
CO. Because β-FXIIa infusion increased BP above
baseline values, these cardiac responses were offset by
progressive and greater vasoconstriction (Figure 1). At
steady-state, β-FXIIa infusion decreased HR by 18+ −5
b.p.m., LVEDV by 65+ −10 μl, LVESV by 27+ −7 μl,
SV by 38+ −5 μl and CO by 24% (−18+ −2 ml/min)
from their corresponding pre-infusion baseline values
(all P<0.05). By contrast, TPR increased by 45%
(0.50+ −0.12 mmHg/ml per min; P<0.05). The net effect
was an increase in steady-state SBP (7+ −2 mmHg),
DBP (4+ −1 mmHg) and MAP (by 6%, or 5+ −2
mmHg; all P<0.05) above corresponding baseline values
(Figure 2).
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Figure 2 Within-group steady-state changes in each haemodynamic variable from pre-infusion baseline (time 0–30 min)
values during the infusion (time 40–90 min) and recovery (time 100–120 min) periods
Values are means+ −S.E.M. Saline control, black bar; human coagulation β-FXIIa infusion, open bar; human coagulation β-FXIIa infusion following 2ADX, grey bar
steady-state. Within-group comparisons: ∗P <0.05 for infusion or recovery compared with baseline values; §P <0.05 for recovery compared with infusion values.
Between-group comparisons: †P <0.05 for infusion or recovery values in the β-FXIIa group compared with corresponding saline control infusion or recovery values;
‡P <0.05 for the infusion or recovery values in the β-FXIIa group compared with the corresponding 2ADX group infusion or recovery values.
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In the 2ADX group, β-FXIIa infusion caused an early
BP dip with recovery, but had no HR effect beyond
the profound reduction subsequent to adrenalectomy.
Infusion caused marked reductions in LVEDV, LVESV
and CO but increased TPR (Figure 1). At steady-state,
β-FXIIa infusion did not change HR, but decreased
LVEDV by 126+ −11 μl, LVESV by 36+ −4 μl, SV by
89+ −9 μl and CO by 39% (−30+ −3 ml/min) from their
corresponding pre-infusion baseline values (all P<0.05).
By contrast, TPR rose by 66% (0.59+ −0.15 mmHg/min
per ml; P<0.05). The net effect was nosigniﬁcant change
in steady-state SBP, but reductions in both DBP (−5+ −
1 mmHg) and MAP (−4+ −1 mmHg, or 6%; both
P<0.05) below corresponding baseline values (Figure 2).
Importantly, there was no difference in absolute terms
in the systemic vasoconstrictor response to β-FXIIa
infusion (TPR) between the two groups (0.50+ −0.12
compared with 0.59+ −0.15 mmHg/ml per min), but
there were signiﬁcant differences between adrenally
intact and 2ADX rats with respect to the effects of β-
FXIIa infusion on SBP (7+ −2 compared with −3+ −2
mmHg), DBP (4+ −1 compared with −5+ −1 mmHg),
MAP (5+ −2 compared with −4+ −1 mmHg), LVEDV
(−65+ −10 compared with −126+ −11 μl), SV (−38+ −5
compared with −89+ −9 μl), HR (−18+ −5 compared
with −4+ −2 b.p.m.) and CO (−18+ −2 compared with
−30+ −3 ml/min) (all P<0.05) (Figure 2).
Haemodynamic changes after β-FXIIa
infusion
In intact rats, the β-FXIIa induced reductions in
HR, LVEDV and CO, and increases in TPR and
BP were sustained throughout the 30 min recovery
period (Figure 1). Post-β-FXIIa infusion, there were
persistent reductions during the steady-state analysis
period (100–120 min) with respect to HR (−26+ −2
b.p.m.), LVEDV (−38+ −8 μl), SV (−32+ −5 μl) and CO
(−17+ −2 ml/min, or −23%) below their respective
baseline values (all P<0.05), while LVESV was no
longer different from baseline. However, TPR remained
signiﬁcantly elevated by 49%, or 0.55+ −0.07 mmHg/ml
per min, above its pre-infusion value (P<0.05). The net
effect was an increase in post-infusion steady-state SBP
(10+ −1 mmHg), DBP (9+ −1 mmHg) and MAP (10+ −1
mmHg or 13%) (all P<0.05) above their corresponding
baseline values (Figure 2).
In the 2ADX group, the β-FXIIa-induced reductions
in LVEDV, LVESV, SV and CO were sustained through
the 30 min recovery period, TPR returned to baseline,
and DBP and MAP remained below their respective
pre-infusion values (Figure 1). At steady-state, post-
β-FXIIa infusion, HR remained unchanged, but there
were persistent reductions in LVEDV (−71+ −14 μl),
LVESV ( −19+ −5 μl), SV (−52+ −10 μl) and CO
(−18+ −3 ml/min or −23%) below their respective
baseline values (all P<0.05). However, TPR returned to
pre-infusion values. The net effect was a decrease in post-
infusion steady-state DBP (−7+ −1 mmHg) and MAP
(−5+ −1 mmHg or −8%, both P<0.05) below their
respective baselines (Figure 2).
In contrast with the infusion steady-state, during
the post-β-FXIIa infusion (recovery) period in absolute
terms the increase in TPR above baseline values was
signiﬁcantlygreaterinadrenallyintactratsthanin2ADX
rats (0.55+ −0.07 compared with 0.15+ −0.07 mmHg/ml
per min; P<0.05), as were SBP (10+ −1 compared with
−2+ −1 mmHg), DBP (9+ −1 compared with −7+ −1
mmHg), MAP (10+ −1 compared with −5+ −1 mmHg)
and HR (−26+ −2 compared with −5+ −1 b.p.m.) (all
P<0.05). By contrast, changes in baseline with respect to
LVEDV, LVESV, SV and CO did not differ between the
two groups (Figure 2).
Plasma coagulation FXIIa and
catecholamine concentrations
Post-recovery plasma coagulation FXIIa absorbance,
which was 0.26+ −0.04 A550 units in the saline control
group, was increased 3-fold by the β-FXIIa infusion
(0.86+ −0.05 A550 units; P<0.05; Figure 3). Similar
absorbance values were achieved by its infusion
into adrenalectomized rats (0.90+ −0.04 A550 units).
Plasma adrenaline and noradrenaline concentrations
were determined to conﬁrm previous observations
indicating that pressor and vasoconstrictor responses
to β-FXIIa infusion were mediated through increases
in adrenally derived catecholamines. In saline-infused
rats, plasma noradrenaline and adrenaline concentrations
measured at the end of the protocol were 2.5+ −1.5 and
1.9+ −1.2 nmol/l respectively (Figure 4). Corresponding
values for β-FXIIa-infused adrenally intact rats were
noradrenaline, 3.6+ −1.4 nmol/l, and adrenaline, 9.8+ −
4.1 nmol/l (P>0.05 and P<0.05 respectively compared
Figure 3 Individual plasma coagulation FXIIa absorbance
measurements obtained at the end of the post-infusion
(recovery) period in the control, β-FXIIa and 2ADX groups
Horizontal bar represents the mean value. ∗P <0.05 for the β-FXIIa compared
with control group values. β-FXIIa and 2ADX group values did not differ.
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Figure 4 Plasma noradrenaline (NE) and adrenaline (E)
concentrations obtained at the end of the post-infusion
(recovery) period in the control, β-FXIIa, and 2ADX groups
Values are means+ −S.E.M. ∗P <0.05 for the β-FXIIa group compared with
control group. †P <0.05 for the β-FXIIa group compared with the 2ADX group.
with saline). By comparison, post-infusion concentra-
tions of noradrenaline and adrenaline adrenalectomized
ratswere0.6+ −0.2and0.6+ −0.2nmol/lrespectively(both,
P<0.05 compared with corresponding values in the
intact adrenal β-FXIIa group).
DISCUSSION
To our knowledge, this is the ﬁrst characterization of
the sympatho-adrenal and haemodynamic responses to
a continuous intravenous infusion of plasma coagulation
β-FXIIa. Our key ﬁnding was that coagulation β-FXIIa
infusion into neurally intact, non-medicated, BN rats
elicited a signiﬁcant vasoconstrictor response that, with
adrenals present, was sustained, along with elevated
plasma adrenaline concentrations and BP, for 30 min
beyond the administration period.
When activated by a conformational change,
endothelial-cellboundFXIIacanbecleavedtoreleaseand
circulate in plasma as the β-FXIIa fragment that retains
proteolytic capacity [2–4]. Plasma β-FXIIa activates
kallikrein rapidly, which in turn activates additional
FXII and further digests FXIIa to β-FXIIa in a positive
feedback cycle of protease activation that generates β-
FXIIa and kallikrein from their respective zymogen
substrates, each of which is present at 1000-fold higher
titres [2–4, 20]. Kallikrein then generates BK-(1–9) from
its plasma substrate kininogen [2,23]. Because increases
inplasmaβ-FXIIaconcentrationweredetectedfollowing
itsinfusion,wecanconcludethatC1-INH(C1inhibitor),
the main endogenous inhibitor of both β-FXIIa and
kallikrein, does not inhibit fully this feedback activation
once an endogenous titre threshold has been reached.
In the extensively studied rat bioassay, bolus
injection of human β-FXIIa elevates plasma BK acutely
by ∼2-fold [10,14]. In turn, BK, acting upon B2
receptors located on adrenal chromafﬁn cells, is a
potent catecholamine secretagogue, which in the rat
releases preferentially adrenaline [12,14,24]. In previous
bioassay experiments, the selective BK B2 antagonist
HOE 140 attenuated catecholamine (plasma adrenaline
by 77%, plasma noradrenaline by 85%), HR and
BP responses to bolus injections of coagulation β-
FXIIa [12]. In addition, in the kininogen-deﬁcient
BN Katholiek rat, a bolus injection of β-FXIIa did
not increase plasma catecholamine concentrations even
though adrenomedullary responsiveness to exogenous
BK was retained, indicating that an intact KKS is
required for β-FXIIa to stimulate adrenomedullary
catecholamine release [14]. These observations suggest
that haemodynamic responses observed during β-FXIIa
in the present experiments represent the summation and
interaction of acute peptide (primarily BK, but also
PACAP), adrenal catecholamine and reﬂex or autonomic
responses to infusion of this coagulation factor, whereas,
because of the short plasma BK half-life [23], haemody-
namic responses observed after its infusion represent the
summation and interaction of catecholamine, non-BK-
peptide (e.g. PACAP) and reﬂex-mediated effects. Our
objective in performing adrenalectomy was to expose
the catecholamine-independent haemodynamic effects of
β-FXIIa infusion in this non-captopril-treated, neurally
intact rat preparation.
Although BK is commonly considered a vasodilator,
when infused continuously into rats at doses between
5a n d8 0 μg/min per kg of body weight it has been
shown to cause an acute dose-dependent increase in
MAPthatisabolishedbypre-treatmentwiththeselective
BK B2 receptor antagonist HOE 140 [25,26]. Hoagland
et al. [25,26] concluded that this BP rise is mediated via
BKB2 receptor-activatedsympatho-excitatorypathways.
Indeed, there is evidence that BK can activate afferent
nerve endings eliciting a sympatho-excitatory reﬂex [27],
and that the increase in amplitude of excitatory junction
potentials is eliminated by HOE 140 [28]. Intrarenal
infusions of BK of 0.5 and 1 μg/min for 5 min [29] or
5–80 μg/min per kg of body weight for 2 min [26], which
increase MAP acutely in a dose-dependent manner, are
eliminated by renal denervation [29] and abolished by
HOE 140 [26], indicating that one set of such afferent
sympatho-excitatory nerve endings originates within the
kidneys. In perfused rat mesenteric arteries pre-infused
with noradrenaline, BK infusions (10−6 to 10−4 M) elicit
a dose-dependent vasoconstrictor response independent
of the endothelium [30]. In conscious rats, intrarenal
infusions of BK (0.5 and 1 μg/min for 5 min) cause
increases in mesenteric arterial resistance by 20% and
33% respectively from baseline which are eliminated
by renal denervation [29]. The increase in TPR during
β-FXIIa infusion in both adrenally intact and 2ADX rats
is consistent with stimulation, by BK, of one or more of
these vasoconstrictor mechanisms.
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TPRincreasedsigniﬁcantlyduringβ-FXIIainfusionin
both experimental groups, but β-FXIIa infusion
decreased LVEDV, LVESV, SV and CO. Each of these
cardiac haemodynamic effects was signiﬁcantly more
profound in the 2ADX group. These ﬁndings probably
represent BK-induced venodilation that was unopposed
by BK-stimulated catecholamine release in the 2ADX
group and therefore augmented. Indeed, as illustrated in
Figure1,inthe2ADXgroupβ-FXIIainfusionelicitedan
immediate transient fall in BP. BK causes endothelium-
dependentvenodilationviaBKB2-receptor-mediatedlib-
eration of NO [31]. Venodilation, in turn lowers LVEDV
(pre-load), an observed effect that was doubled, in the
presentexperiments,byadrenalectomy(−126+ −11com-
pared with −65+ −10 μl, P<0.05). Of note, mice lacking
theadrenaline-synthesizingenzymephenylethanolamine
N-methyltransferase, have 22% lower LVEDV com-
pared with wild-type controls [32], conﬁrming that
plasma adrenaline is important in maintaining pre-load.
An increase in capillary endothelial permeability will
also reduce pre-load. In rats, BK-(1–9) infusion increases
rapidly mesenteric capillary permeability (measured as
the albumin leakage index) from 5% to 95% via BK B1
and B2 receptor-dependent mechanisms [33].
β-FXIIa infusion also reduced LVESV in both groups
of rats. The consequent reduction in SV was aug-
mented by adrenalectomy (−89+ −9 μl compared with
−38+ −5 μl, P<0.05), likely due to the combination of
decreased end-diastolic myocyte stretch, and diminished
inotropy due to the profound reduction in circulating
catecholamines. In both groups, CO (the product of SV
and HR) fell during β-FXIIa infusion; in intact rats, this
was due to a decrease in both components, whereas in
adrenalectomized rats this reﬂected the more profound
reduction in SV.
Adrenalectomy caused a marked reduction in baseline
HR(Figure1).β-FXIIainfusionhadnoadditionaleffect,
whereas in rats with intact adrenals, β-FXIIa infusion
elicited a signiﬁcant fall in HR. This chronotropic
response would be anticipated from prior studies
in conscious rats; a 90 min intravenous infusion of
adrenaline increased plasma concentrations 90-fold,
by 18.4 nmol/l, and increased MAP signiﬁcantly, but
caused only a transient, non-signiﬁcant decrease in HR
[34]. In the anaesthetized, ganglion-blocked, captopril-
treated bioassay preparation 1 μg/kg intravenous β-
FXIIa injection evoked a 170-fold increase in plasma
adrenaline and increased HR from 315 to 408 b.p.m. [14].
Since endogenous NO has been shown to augment
vagal tone, one explanation for the slower HR observed
invivoagainmaybeBK-inducedNOgeneration[35–37].
BKalsoactsdirectlyonthesino-atrialnode,viatheBKB2
receptor, to lower HR [37]. In BK B2 receptor knockout
mice basal HR is elevated compared with littermate
controls[38],andpharmacologicalblockadebytheBKB2
receptor antagonist HOE 140 increases HR in both rats
[39] and humans [40]. A second potential explanation
for the slower HR observed in rats with intact adrenal
glands is that β-FXIIa induced increases in PACAP
[13], which lowers HR by liberating acetylcholine from
postganglionicparasympatheticnerves[41].Importantly,
a signiﬁcant increase in SBP (7+ −2 mmHg), which would
reduce HR rate reﬂexively by stimulating the arterial
baroreceptor reﬂex, was observed only in the adrenally
intact group. Each or a combination of these several HR
modulating pathways could contribute to the observed
negative chronotropic response to β-FXIIa.
Once the β-FXIIa infusion ended, TPR reverted
promptly to baseline in the 2ADX group, but remained
signiﬁcantly elevated, along with BP, in the intact group
of rats. The time course over which this occurred in the
2ADX is consistent with its rapid degradation in plasma
[23], with dissipation in parallel with its sympatho-
excitatory effects. By contrast, any BK-induced re-
ductions in pre-load due to vasodilation or increased
capillary permeability would be sustained throughout
therecoveryperiod.Thepresentﬁndingsindicatethatthe
vasoconstrictor after effects of coagulation β-FXIIa
require a functioning adrenal gland, and are mediated in
partbyplasmaadrenaline,apotentvascularα-adrenergic-
receptor-mediated peripheral vasoconstrictor in the
rat [34,42].
However, because the plasma half-life of catecholam-
ines in the rat is 90 s or less [43], haemodynamic
responses to BK B2 receptor-stimulated catecholamine
release would be expected to dissipate rapidly. Thus,
other vasoconstrictor mechanisms must be invoked to
accountforthesustainedvasoconstrictionobservedinthe
present experiments. One attractive candidate is PACAP,
aneurotransmitterthatcanbothincreasesplanchnicsym-
pathetic nerve activity [44] and also stimulate the adrenal
chromafﬁn membrane-associated PACAP PAC-1 re-
ceptor[45]toreleaseadrenalinepreferentiallyintoplasma
[13,46]. In rats, the adrenal gland is the organ with the
second highest concentration of PACAP [47]. Previous
bioassay rat studies, using a pharmacological inhibitor,
demonstrated that a signiﬁcant proportion of the acute
BP effect of bolus β-FXIIa is mediated via the PAC-1 re-
ceptor [13]. This effect is durable: plasma adrenaline con-
centrations in rats remain 233% above baseline 60 min
after a 10 min PACAP infusion (50 μMa t3 μl/min)
[48].
To summarize, in the present experiments, we demon-
strate that short-term intravenous infusion of plasma
coagulation β-FXIIa exerts signiﬁcant haemodynamic
effects, which require an intact adrenal gland for their
full expression. These include an increase in peripheral
vasoconstriction that exceeds reductions in pre-load and
CO resulting overall in a signiﬁcant increase in BP. Such
vasoconstriction is, in part, adrenal-independent, but in
rats with adrenals in situ vasoconstriction persists for at
least 30 min after β-FXIIa infusion.
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It is now appreciated that plasma coagulation
FXIIa concentrations are elevated, in some instances
more than 10-fold, in many patients with primary
essential hypertension [5], diabetes [49], coronary
heart disease [6,7] and chronic renal failure [49–52],
conditions associated with increased risk of stroke
and myocardial infarction and often characterized by
vascular inﬂammation, are increased more than 5-fold
after thrombolytic therapy [53] and remain elevated for
6 weeks following myocardial infarction [18].
In such states, chronic coagulation β-FXIIa elevation
may disturb further already abnormal BP regulatory
mechanisms, and increase the risk of adverse cardio-
vascular events. With FXIIa inhibitors currently under
development [54], there may indeed be an opportunity
to exploit this pathway as therapy of hypertension in
otherwise difﬁcult-to-treat conditions characterized by
increasedFXIIainplasma,suchasend-stagerenaldisease.
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MATERIALS AND METHODS
Calibration of LV RVU from
echocardiographic volume indices
Male BN rats weighing 250–300 g (n=6) were studied
followingisoﬂuraneinhalation(0.75–1.25%;Halocarbon
Laboratories) delivered with a mixture of oxygen (BOC
Gases) using a Fluotec Mark 2 vaporizer (Cyprane) at a
gasﬂowrateof2litres/min.Amicro-tippressure–volume
catheter transducer (SPR-838; Millar Instruments) linked
to a control unit (MPCU-200; Millar Instruments) and
connected to a MacLab/8 data acquisition system (AD
Instruments) driven by PowerLab Chart v.4.2 software
(AD Instruments) was advanced retrogradely into the
LV from the right common carotid artery. Baseline
LVBP (mmHg) was derived from the BP waveform
and volume (RVU) was derived from the volume
waveform. These measurements were recorded continu-
ously at 2 kHz sampling rate (Figure S1, right-hand
panels).
Concurrently, an anatomical M-mode echocardio-
graphic assessment with two-dimensional monitoring
using a Vevo 770 high-resolution imaging system (Visual
Sonics)withacardiovascularscanheadtransducer(model
RMV 710B) was used to measure the short-axis LVIDs
(LV internal diameter end-systole) and LVIDd (LV
internal diameter end-diastole) in mm (Figure S1, left-
hand panels). The Teichholz formula [1,2], which deﬁnes
the relationship between blood volume (V)o ft h e
ventricle and the short axis inner diameter (D)a s
V =(7D3)/(2.4+D), was used to calculate LVEDV and
LVESV from LVIDd and LVIDs respectively (Vevo 770
Software System Version 2.2.3; Visual Sonics). After
baseline BP and volume measurements were acquired,
the IVC (inferior vena cava) was occluded by applying
a cotton tip applicator (Figure S1, bottom panel). A
minimum of ﬁve baseline and ﬁve responses to IVC
occlusion was recorded per animal. Numerical data
were ﬁtted with a second-order polynomial trendline
using the Sigma Stat program (version 2.03; SPSS). The
relationship between RVU (y) and echocardiographic
volume (x) could be described by the equation
y=−9×10−5x2 +0.0706x+10.138 (Figure S2).
The conductance catheter method (SPR-838; Millar
Instruments) has been validated in the Sprague–Dawley
rat [3], using trans-thoracic echocardiography as a
reference. Bland–Altman analyses for quantiﬁcation of
average differences were, for LVEDV, 30+ −50 μl; for
LVESV, −40+ −30 μla n df o rS V ,3 + −20 μl. Absolute
values for these variables, derived using the conductance
catheter in these experiments, were similar to baseline
values in the present experiment.
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Figure S1 Simultaneous acquisition of LV volume measurements by echocardiography and by micro-tip pressure–volume
catheter transducer
Representative traces of echocardiographic assessment of the short axis LVIDs and LVIDd (left panels). LVEDV and LVESV were calculated from LVIDd and LVIDs using
the Teichholz formula V =(7D3)/(2.4+D). Concurrently, LVBP (mmHg) and RVU were recorded continuously using a micro-tip pressure–volume catheter transducer
(right panels). Data were acquired at baseline (top panels) and during IVC occlusion (bottom panels).
Figure S2 Derivation of RVU from echocardiographic
volumes
LV volumes estimated from a micro-tip pressure–volume catheter transducer
reported as RVU versus calculated volumes recorded concurrently from an
anatomical M-mode echocardiographic assessment of the left ventricle. Numerical
data were ﬁtted with a second-order polynomial trendline. The relationship
between RVU (y) and echocardiographic volume (x) could be described by the
equation −9×10−5x2 +0.0706x +10.138.
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